These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 10970856)

  • 1. Extracellular domains drive homo- but not hetero-dimerization of erbB receptors.
    Ferguson KM; Darling PJ; Mohan MJ; Macatee TL; Lemmon MA
    EMBO J; 2000 Sep; 19(17):4632-43. PubMed ID: 10970856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers.
    Muthuswamy SK; Gilman M; Brugge JS
    Mol Cell Biol; 1999 Oct; 19(10):6845-57. PubMed ID: 10490623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding specificities and affinities of egf domains for ErbB receptors.
    Jones JT; Akita RW; Sliwkowski MX
    FEBS Lett; 1999 Mar; 447(2-3):227-31. PubMed ID: 10214951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bivalence of EGF-like ligands drives the ErbB signaling network.
    Tzahar E; Pinkas-Kramarski R; Moyer JD; Klapper LN; Alroy I; Levkowitz G; Shelly M; Henis S; Eisenstein M; Ratzkin BJ; Sela M; Andrews GC; Yarden Y
    EMBO J; 1997 Aug; 16(16):4938-50. PubMed ID: 9305636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers.
    Lenferink AE; Pinkas-Kramarski R; van de Poll ML; van Vugt MJ; Klapper LN; Tzahar E; Waterman H; Sela M; van Zoelen EJ; Yarden Y
    EMBO J; 1998 Jun; 17(12):3385-97. PubMed ID: 9628875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.
    Graus-Porta D; Beerli RR; Daly JM; Hynes NE
    EMBO J; 1997 Apr; 16(7):1647-55. PubMed ID: 9130710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterodimerization of the epidermal-growth-factor (EGF) receptor and ErbB2 and the affinity of EGF binding are regulated by different mechanisms.
    Johannessen LE; Haugen KE; østvold AC; Stang E; Madshus IH
    Biochem J; 2001 May; 356(Pt 1):87-96. PubMed ID: 11336639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
    Pinkas-Kramarski R; Lenferink AE; Bacus SS; Lyass L; van de Poll ML; Klapper LN; Tzahar E; Sela M; van Zoelen EJ; Yarden Y
    Oncogene; 1998 Mar; 16(10):1249-58. PubMed ID: 9546426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligand-independent dimerization of oncogenic v-erbB products involves covalent interactions.
    Adelsman MA; Huntley BK; Maihle NJ
    J Virol; 1996 Apr; 70(4):2533-44. PubMed ID: 8642683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The single transmembrane domains of ErbB receptors self-associate in cell membranes.
    Mendrola JM; Berger MB; King MC; Lemmon MA
    J Biol Chem; 2002 Feb; 277(7):4704-12. PubMed ID: 11741943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural arrangement of the active back-to-back dimer in N-glycosylated ErbB receptors is regulated by heterodimerization.
    Mashayekh-Poul R; Azimzadeh-Irani M; Masoomi-Nomandan SZ
    Mol Biol Res Commun; 2023; 12(3):95-107. PubMed ID: 37525663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors.
    Burgess AW; Cho HS; Eigenbrot C; Ferguson KM; Garrett TP; Leahy DJ; Lemmon MA; Sliwkowski MX; Ward CW; Yokoyama S
    Mol Cell; 2003 Sep; 12(3):541-52. PubMed ID: 14527402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative constraints underlie the ErbB specificity of epidermal growth factor-like ligands.
    van der Woning SP; van Rotterdam W; Nabuurs SB; Venselaar H; Jacobs-Oomen S; Wingens M; Vriend G; Stortelers C; van Zoelen EJ
    J Biol Chem; 2006 Dec; 281(52):40033-40. PubMed ID: 17032651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The neuregulin-I/ErbB signaling system in development and disease.
    Britsch S
    Adv Anat Embryol Cell Biol; 2007; 190():1-65. PubMed ID: 17432114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors.
    Zhan L; Xiang B; Muthuswamy SK
    Cancer Res; 2006 May; 66(10):5201-8. PubMed ID: 16707444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ErbB/HER receptor protein-tyrosine kinases and cancer.
    Roskoski R
    Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disabling receptor ensembles with rationally designed interface peptidomimetics.
    Berezov A; Chen J; Liu Q; Zhang HT; Greene MI; Murali R
    J Biol Chem; 2002 Aug; 277(31):28330-9. PubMed ID: 12011054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases.
    Spencer KS; Graus-Porta D; Leng J; Hynes NE; Klemke RL
    J Cell Biol; 2000 Jan; 148(2):385-97. PubMed ID: 10648571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor (EGF) induces oligomerization of soluble, extracellular, ligand-binding domain of EGF receptor. A low resolution projection structure of the ligand-binding domain.
    Lax I; Mitra AK; Ravera C; Hurwitz DR; Rubinstein M; Ullrich A; Stroud RM; Schlessinger J
    J Biol Chem; 1991 Jul; 266(21):13828-33. PubMed ID: 1856216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.